Bethesda, Md. – On October 2, 2015 AABB received a restricted charitable grant from Cerus Corporation in the amount of $60,000 to support the Association’s effort in further developing hemovigilance program participation in the United States.
“This one-year agreement further underscores that an investment in hemovigilance is critical to ensure quality patient outcomes,” said Miriam A. Markowitz, AABB CEO. “With the establishment of the AABB Center for Patient Safety in 2008, AABB has been at the forefront of hemovigilance activities dedicated to improving patient safety and the quality of health care delivery. We appreciate the support from Cerus Corporation to further our mission.”
The restricted grant will be used to:
- Engage in hospital outreach efforts to expand hemovigilance activities by hospitals to increase the hemovigilance commitment and permit statistically meaningful analysis.
- Provide hemovigilance training to hospital sites participating in the hemovigilance program.
- Develop a United States hemovigilance protocol, using the framework of the National Healthcare Safety Network (NHSN) Biovigilance Component’s Hemovigilance Module, to collect reported adverse event data associated with the use of pathogen-reduced products.
- Review and harmonize data collection forms and processes to encourage innovation and adoption in all blood components, transfusion medicine and blood banking practices.
- Pursue dissemination of scholastic findings resulting from research.
“We are proud to support AABB in their endeavor to further advance a U.S. hemovigilance system,” said William ’Obi’ M. Greenman, President and CEO of Cerus. “AABB’s efforts to collect adverse event data are in line with our work to reduce the risk of transfusion-transmitted diseases through pathogen reduction.”
The AABB Center for Patient Safety is dedicated to confidentially analyzing data on adverse reactions and incidents associated with blood transfusions in order to identify and communicate best practices to improve patient safety. Currently, 85 hospitals nationwide receive support for their internal hemovigilance activities and participate in targeted interventions and analyses through the AABB Center for Patient Safety.
“Hemovigilance activities must remain aligned with the current advances in our industry,” said James P. AuBuchon, MD, FCAP, FRCP (Edin), President and CEO of Puget Sound Blood Center. “Tracking the transfusion of pathogen inactivated components and keeping up with adoption of hemovigilance programs and reporting is fundamental to identifying trends and learning best practices to enhance transfusion safety for years to come.”
AABB is an international, not-for-profit association representing individuals and institutions involved in transfusion medicine, cellular therapies and patient blood management. The association is committed to improving health by developing and delivering standards, accreditation and educational programs that focus on optimizing patient and donor care and safety. AABB membership consists of nearly 2,000 institutions and 8,000 individuals, including physicians, nurses, scientists, researchers, administrators, medical technologists and other health care providers. Members are located in more than 80 countries. For more information, visit www.aabb.org.